A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Phase 1 Unknown 17 enrolled Oncolys BioPharma Inc

NaSingle-groupOpen-labelTreatment

Summary

This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.

Timeline

Start: 2015-03
Primary completion: 2019-06
Completion: 2019-08

Publications

Heath EI, Weise A, Vaishampayan U, Danforth D, Ungerleider RS, Urata Y. Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2022 Apr;40(2):300-307. doi: 10.1007/s10637-021-01180-9. Epub 2021 Oct 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OBP-801	Small molecule	1 mg/m2	Intravenous
Subject	OBP-801	Small molecule	2 mg/m2	Intravenous
Subject	OBP-801	Small molecule	2.8 mg/m2	Intravenous

A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications